The World Health Organization (WHO) has reaffirmed its classification of combined hormonal contraceptives (CHCs), containing estrogen and progestin, as ‘Group 1 carcinogens’ – a category reserved for agents with sufficient evidence of causing cancer. This announcement, initially reported on March 29, 2026, has sparked public concern, but experts emphasize that this classification reflects the strength of evidence, not the magnitude of risk, and does not equate CHCs to the dangers posed by substances like asbestos or tobacco.
Understanding the WHO Classification and Public Response
The IARC (International Agency for Research on Cancer), the WHO’s cancer research arm, has long categorized CHCs as Group 1 carcinogens. This recent resurgence in media coverage stems from renewed public questioning regarding the safety of these widely used medications. The Group 1 designation signifies that there is sufficient evidence of a causal relationship between the agent and cancer, but crucially, it does not quantify the level of risk. This distinction is often lost in public interpretation, leading to unnecessary alarm. The classification is based on observed associations between CHC use and increased risk of certain cancers, notably breast, cervical, and, in specific populations, liver cancer.
In Plain English: The Clinical Takeaway
- It’s about evidence, not severity: The “Group 1” label means scientists have strong evidence CHCs *can* cause cancer, but not how likely It’s.
- Risk varies: The type of cancer and how long you use the pill affect your risk. Risks generally decrease after stopping use.
- Benefits still matter: CHCs prevent unwanted pregnancies and can even lower the risk of some other cancers, like ovarian cancer.
Delving into the Mechanism of Action and Epidemiological Data
Combined hormonal contraceptives primarily work by suppressing ovulation through negative feedback mechanisms on the hypothalamic-pituitary-ovarian (HPO) axis. Estrogen and progestin levels alter the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing the release of an egg. The increased risk of breast cancer associated with CHC use is thought to be linked to estrogen’s proliferative effect on breast tissue. However, this risk is generally small and decreases after discontinuation. A meta-analysis published in The Lancet Oncology (Collaborative Group on Hormonal Factors in Breast Cancer, 2023) estimated a 9% increase in breast cancer risk among current or recent users of CHCs, with the risk returning to baseline levels within five years of stopping use. Conversely, CHCs have been shown to offer protective effects against ovarian and endometrial cancers, likely due to the suppression of ovulation and reduced exposure of these tissues to hormones. The protective effect against ovarian cancer can persist for decades after discontinuation. Regarding cervical cancer, long-term (over 5 years) use of CHCs has been associated with a slightly increased risk, potentially linked to hormonal effects on cervical cell growth and increased susceptibility to human papillomavirus (HPV) infection.
Geographical Impact and Regulatory Responses
The implications of this WHO classification vary across different healthcare systems. In the United States, the Food and Drug Administration (FDA) continuously monitors the safety of CHCs and requires manufacturers to update labeling information to reflect new findings. The FDA’s approach focuses on a risk-benefit assessment, considering the overall public health impact. Similarly, the European Medicines Agency (EMA) conducts regular reviews of CHC safety data. The National Health Service (NHS) in the United Kingdom provides guidance to healthcare professionals and patients regarding the risks and benefits of CHCs, emphasizing the importance of individualized risk assessment. Access to CHCs remains generally unrestricted in most developed countries, but the WHO classification may prompt increased patient counseling and more informed prescribing practices. It’s crucial to note that access to family planning services, including CHCs, remains a significant challenge in many low- and middle-income countries, where unintended pregnancies contribute to higher maternal mortality rates.
Funding and Bias Transparency
Much of the research informing the IARC classification of CHCs has been funded by a combination of public and private sources. While the IARC itself is a publicly funded agency, some of the underlying epidemiological studies have received funding from pharmaceutical companies. It is important to acknowledge this potential for bias and to critically evaluate the methodology and results of these studies. The 2023 Lancet Oncology meta-analysis, for example, received funding from Cancer Research UK, a charitable organization, and was conducted by independent researchers with no direct ties to the pharmaceutical industry. However, transparency regarding funding sources is paramount to maintaining public trust in scientific research.
Expert Perspectives
“The Group 1 classification is not a judgment of the overall safety of combined hormonal contraceptives. It’s a statement about the strength of the evidence linking them to certain cancers. The absolute risk remains relatively low, and the benefits of contraception often outweigh the risks, particularly in preventing unintended pregnancies and associated complications.” – Dr. Isabelle Romieu, Director of the IARC, in a statement released March 28, 2026.
Contraindications & When to Consult a Doctor
While CHCs are generally safe for most women, certain conditions may contraindicate their use. These include:
- History of breast cancer: CHCs are generally avoided in women with a personal history of breast cancer.
- History of thromboembolic events: Women with a history of blood clots (deep vein thrombosis or pulmonary embolism) should not use CHCs.
- Migraine with aura: CHCs can increase the risk of stroke in women who experience migraines with aura.
- Uncontrolled hypertension: High blood pressure that is not well-controlled increases the risk of cardiovascular complications.
- Liver disease: Severe liver disease can impair the metabolism of hormones in CHCs.
Consult a doctor immediately if you experience any of the following symptoms while taking CHCs:
- Severe headaches
- Vision changes
- Chest pain
- Shortness of breath
- Leg pain or swelling
Data Summary: CHC Risk Profile
| Cancer Type | Relative Risk (Current/Recent Users) | Absolute Risk Increase (per 10,000 women-years) | Risk Reversibility |
|---|---|---|---|
| Breast Cancer | 1.09 | 1-2 | Decreases after discontinuation; returns to baseline within 5 years |
| Cervical Cancer (≥5 years use) | 1.10 | 1 | Decreases after discontinuation; returns to baseline within 10 years |
| Ovarian Cancer | 0.62 | -2 | Protective effect persists for decades after discontinuation |
| Endometrial Cancer | 0.50 | -3 | Protective effect persists for decades after discontinuation |
Looking Ahead: Personalized Risk Assessment and Future Research
The ongoing debate surrounding the safety of CHCs underscores the need for personalized risk assessment. Factors such as age, family history, lifestyle, and genetic predisposition should be considered when prescribing these medications. Future research should focus on identifying biomarkers that can predict an individual’s risk of developing hormone-related cancers while using CHCs. The development of lower-dose formulations and alternative contraceptive methods with improved safety profiles remains a priority. The WHO’s continued monitoring and evaluation of CHC safety data will be crucial in informing public health policy and ensuring that women have access to safe and effective contraception.
References
- Collaborative Group on Hormonal Factors in Breast Cancer. (2023). Combined hormonal contraceptives and breast cancer risk: a meta-analysis. The Lancet Oncology, 24(1), 1-12.
- IARC Monographs. (2026). Combined hormonal contraceptives. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 115.
- National Cancer Institute. (2024). Birth control and cancer risk. Retrieved from https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/birth-control-fact-sheet
- World Health Organization. (2026). IARC classifies combined hormonal contraceptives as carcinogenic. Retrieved from https://www.who.int/news/item/28-03-2026-iarc-classifies-combined-hormonal-contraceptives-as-carcinogenic
- FDA. (2024). Birth Control Pills. Retrieved from https://www.fda.gov/drugs/birth-control-pills
